S Gerald Sandler

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3263655/publications.pdf

Version: 2024-02-01

566801 433756 1,059 58 15 31 citations h-index g-index papers 61 61 61 626 docs citations times ranked citing authors all docs

#	Article	IF	Citations
1	It's time to phase out "serologic weak D phenotype―and resolve D types with <i>RHD</i> genotyping including weak D type 4. Transfusion, 2020, 60, 855-859.	0.8	27
2	The emperor and the blood center. Transfusion, 2019, 59, 3559-3559.	0.8	0
3	Does transfusion of Asianâ€type DEL red blood cells to D– recipients cause D alloimmunization?. Transfusion, 2019, 59, 2455-2458.	0.8	6
4	Serological weak D phenotypes: a review and guidance for interpreting the RhD blood type using the <i><i><scp>RHD</scp></i> genotype. British Journal of Haematology, 2017, 179, 10-19.</i>	1.2	76
5	A Guide to Terminology for Rh Immunoprophylaxis. Obstetrics and Gynecology, 2017, 130, 633-635.	1.2	8
6	Nonhemolytic passenger lymphocyte syndrome. Transfusion, 2017, 57, 2942-2945.	0.8	10
7	DEL phenotype. Immunohematology, 2017, 33, 125-132.	0.2	25
8	Delayed hemolytic transfusion reaction captured by a cell phone camera. Transfusion, 2016, 56, 1006-1007.	0.8	1
9	A model for integrating molecular-based testing in transfusion services. Blood Transfusion, 2016, 14, 566-572.	0.3	11
10	Financial implications of $\langle i\rangle$ RHD $\langle i\rangle$ genotyping of pregnant women with a serologic weak D phenotype. Transfusion, 2015, 55, 2095-2103.	0.8	47
11	Immunosuppressive medication and alloimmunization to red blood cell antigens. Transfusion, 2015, 55, 224-224.	0.8	O
12	The entity of immunoglobulin <scp>A</scp> –related anaphylactic transfusion reactions is not evidence based. Transfusion, 2015, 55, 199-204.	0.8	48
13	Assisted reproductive technology: an uncommon, but increasing, cause of parentâ€child ABO discrepancy. Transfusion, 2015, 55, 2048-2049.	0.8	1
14	Miscounting even one lymphocyte in the Kleihauerâ€Betke (acidâ€elution) assay can result in overdosing Rh immune globulin. Transfusion, 2015, 55, 2069-2069.	0.8	2
15	Blood group genotyping: faster and more reliable identification of rare blood for transfusion. Lancet Haematology,the, 2015, 2, e270-e271.	2.2	8
16	Rh Immunoprophylaxis for Women With a Serologic Weak D Phenotype. Laboratory Medicine, 2015, 46, 190-194.	0.8	6
17	It's time to phase in <i><scp>RHD</scp></i> genotyping for patients with a serologic weak <scp>D</scp> phenotype. Transfusion, 2015, 55, 680-689.	0.8	157
18	Policies and Procedures Related to Testing for Weak D Phenotypes and Administration of Rh Immune Globulin: Results and Recommendations Related to Supplemental Questions in the Comprehensive Transfusion Medicine Survey of the College of American Pathologists. Archives of Pathology and Laboratory Medicine, 2014, 138, 620-625.	1.2	35

#	Article	IF	CITATIONS
19	Eculizumab Reduces Red Blood Cell Transfusions in Non-Renal Solid Organ Transplant Patients Diagnosed with Post Transplant Atypical Hemolytic Uremic Syndrome (PT-aHUS). Blood, 2014, 124, 4183-4183.	0.6	0
20	Proficiency tests reveal the need to improve laboratory assays for fetomaternal hemorrhage for <scp>Rh</scp> immunoprophylaxis. Transfusion, 2013, 53, 2098-2102.	0.8	8
21	Immunosuppressive protocols for transplantation and certain hematologic malignancies can prevent the primary immune response to the D blood group antigen. Immunohematology, 2013, 29, 110-114.	0.2	5
22	Postpartum Rh Immunoprophylaxis. Obstetrics and Gynecology, 2012, 120, 1428-1438.	1.2	18
23	New Laboratory Procedures and Rh Blood Type Changes in a Pregnant Woman. Obstetrics and Gynecology, 2012, 119, 426-428.	1.2	6
24	Anaphylactic transfusion reactions. Transfusion, 2011, 51, 2265-2266.	0.8	11
25	The status of pathogen-reduced plasma. Transfusion and Apheresis Science, 2010, 43, 393-399.	0.5	12
26	Effectiveness of the Rhlg Dose Calculator. Archives of Pathology and Laboratory Medicine, 2010, 134, 967-968.	1.2	5
27	Laboratory methods for Rh immunoprophylaxis: a review. Immunohematology, 2010, 26, 92-103.	0.2	14
28	Nonhemolytic passenger lymphocyte syndrome: donor-derived anti-M in an M+ recipient of a multiorgan transplant. Immunohematology, 2009, 25, 20-23.	0.2	9
29	Special requirements for blood transfusions. Clinical Advances in Hematology and Oncology, 2009, 7, 501-3.	0.3	0
30	Washed and Volume-Reduced Blood Components. , 2007, , 410-418.		1
31	It is time to bring back solvent???detergent plasma. Current Opinion in Hematology, 2007, 14, 640-641.	1.2	5
32	Radiofrequency identification technology can standardize and document blood collections and transfusions. Transfusion, 2007, 47, 763-770.	0.8	24
33	How I manage patients suspected of having had an IgA anaphylactic transfusion reaction. Transfusion, 2006, 46, 10-13.	0.8	61
34	Kurt Stern (1909-2003). Transfusion Medicine Reviews, 2006, 20, 80-83.	0.9	0
35	Temperature-Sensitive Labels for Containers of RBCs. American Journal of Clinical Pathology, 2006, 126, 406-410.	0.4	25
36	Human platelet alloantigen systems in three Chinese ethnic populations. Immunohematology, 2006, 22, 6-10.	0.2	9

#	Article	IF	CITATIONS
37	The case for pathogen inactivation of blood components. Current Opinion in Hematology, 2005, 12, 471-472.	1.2	3
38	Immune thrombocytopenic purpura $\hat{a} \in \text{``current management practices. Expert Opinion on Pharmacotherapy, 2004, 5, 2515-2527.}$	0.9	20
39	The risks of blood transfusions involve donors as well as patients. Current Opinion in Hematology, 2004, 11, 321-322.	1.2	0
40	Review: immune thrombocytopenic purpura: an update for immunohematologists. Immunohematology, 2004, 20, 112-117.	0.2	6
41	Equivalence of spray-dried K ₂ EDTA, spray-dried K ₃ EDTA, and liquid K ₃ EDTA anticoagulated blood samples for routine blood center or transfusion service testing. Immunohematology, 2003, 19, 117-121.	0.2	2
42	Risks of blood transfusion and their prevention. Clinical Advances in Hematology and Oncology, 2003, 1, 307-13.	0.3	33
43	Transportation and Other Blood System Issues Related to Disasters: Washington, DC Experience of September 11, 2002. Vox Sanguinis, 2002, 83, 367-370.	0.7	6
44	Intravenous Rh immune globulin for treating immune thrombocytopenic purpura. Current Opinion in Hematology, 2001, 8, 417-420.	1.2	12
45	Treating immune thrombocytopenic purpura and preventing Rh alloimmunization using intravenous Rho (D) immune globulin. Transfusion Medicine Reviews, 2001, 15, 67-76.	0.9	15
46	Serologic aspects of treating immune thrombocytopenic purpura using intravenous Rh immune globulin. Immunohematology, 2001, 17, 106-110.	0.2	5
47	The cost of treating immune thrombocytopenic purpura using intravenous Rh immune globulin versus intravenous immune globulin., 2000, 63, 156-158.		13
48	Successful prevention of post-transfusion Rh alloimmunization by intravenous Rho (D) immune globulin (WinRho SD)., 1999, 60, 245-247.		24
49	Impact of Innovations on Transfusion Medicine. Archives of Pathology and Laboratory Medicine, 1999, 123, 672-676.	1.2	2
50	The Diego blood group system-an update. Immunohematology, 1999, 15, 159-162.	0.2	3
51	Intravenous Anti-D Treatment for Immune Thrombocytopenic Purpura. Blood, 1998, 91, 2624-2625.	0.6	9
52	Immunoprophylaxis using intravenous Rh immune globulin should be standard practice when selected D-negative patients are transfused with D-positive random donor platelets. Immunohematology, 1998, 14, 133-137.	0.2	11
53	Intravenous Anti-D Treatment for Immune Thrombocytopenic Purpura. Blood, 1998, 91, 2624-2625.	0.6	2
54	Case report: reporting anti-G as anti-C+D may have misleading clinical implications. Immunohematology, 1997, 13, 58-60.	0.2	0

#	Article	IF	CITATIONS
55	lgA anaphylactic transfusion reactions. Transfusion Medicine Reviews, 1995, 9, 1-8.	0.9	180
56	Immune-mediated hemolysis in a postoperative patient Case report: anti-U and differential diagnosis. Immunohematology, 1993, 9, 41-46.	0.2	4
57	Blood Transfusion Therapy in the Rear Hospital During the Yom Kippur War (October 1973). Military Medicine, 1977, 142, 49-53.	0.4	5
58	Simultaneous Occurrence of "American Burkitt's Lymphoma―in Neighbors. New England Journal of Medicine, 1973, 288, 562-563.	13.9	23